Frontiers in Oncology · 2022 · 10 citations · 30 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyMolecular OncologyBreast Cancer PharmacotherapyNext-generation Sequencing In OncologyOncology PharmacologySystems Pharmacology In CancerAnticancer ActivityAnticancer Natural ProductsBreast Cancer Resistance MechanismsCell Viability AssaysDna Damage InductionDna Strand Break RepairPhytochemicals In Cancer PreventionTriple-negative Breast Cancer Therapy
Objective Triple-negative breast cancer (TNBC) is distinguished by early recurrence and metastases, a high proclivity for treatment resistance, and a lack of targeted medicines, highlighting the importance of developing innovative therapeutic techniques. Salvia chinensis Benth (SCH) has been widely studied for its anticancer properties in a variety of cancers. However, its significance in TNBC treatment is rarely discussed. Our study investigated the anticancer effect of SCH on TNBC and the underlying mechanisms. Methods First, we used clonogenic, cell viability, flow cytometry, and Transwell assays to assess the effect of SCH on TNBC. Bioinformatic studies, especially network pharmacology-based analysis and RNA sequencing analysis, were performed to investigate the constituents of SCH and its molecular mechanisms in the suppression of TNBC. High-performance liquid chromatography and thin-layer chromatography were used to identify two major components, quercetin and β-sitosterol. Then, we discovered the synergistic cytotoxicity of quercetin and β-sitosterol and assessed their synergistic prevention of cell migration and invasion. Breast cancer xenografts were also created using MDA-MB-231 cells to test the synergistic therapeutic impact of quercetin and β-sitosterol on TNBC in vivo . The impact on the DNA damage and repair pathways was investigated using the comet assay and Western blot analysis. Results Our findings showed that SCH decreased TNBC cell growth, migration, and invasion while also inducing cell death. We identified quercetin and β-sitosterol as the core active components of SCH based on a network pharmacology study. According to RNA sequencing research, the p53 signaling pathway is also regarded as a critical biological mechanism of SCH treatment. The comet assay consistently showed that SCH significantly increased DNA damage in TNBC cells. Our in vivo and in vitro data revealed that the combination of quercetin and β-sitosterol induced synergistic cytotoxicity and DNA damage in TNBC cells. In particular, SCH particularly blocked the inter-strand cross-link repair mechanism and the double-strand breach repair caused by the homologous recombination pathway, in addition to inducing DNA damage. Treatment with quercetin and β-sitosterol produced similar outcomes. Conclusion The current study provides novel insight into the previously unknown therapeutic potential of SCH as a DNA-damaging agent in TNBC.
30
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · Clinical Cancer Research · 2007 · 5.1K citations · Full text
DNA damage activates p53 through a phosphorylation–acetylation cascade
Kazuyasu Sakaguchi, Julio E. Herrera, Shinichi Saito et al. · Genes & Development · 1998 · 1.2K citations · Full text